

Express Mail Label No.: EV312712165US  
Date of Deposit: September 30, 2003

Attorney Docket No.: 33239-301B

RECEIVED  
OCT 10 2003  
TECH CENTER 1600/2900

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT: Ellington et al.  
SERIAL NUMBER: 09/666,870 EXAMINER : Jon D. Epperson, Ph.D.  
FILING DATE: September 20, 2000 ART UNIT : 1639  
FOR: Methods and Apparatus for Identifying Allosterically Regulated Ribozymes

**MAIL STOP IDS**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Information Disclosure Statement is being filed after the mailing date of the first Office Action, but before the mailing date of either a final action under 37 C.F.R. §1.113 or a Notice of Allowance under 37C.F.R. §1.311. The fee of \$180.00 as set for in 37C.F.R. §1.17(p) is enclosed.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.


By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANT: Ellington, et al.  
U.S.S.N.: 09/666,870

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No.: 23239-301B.

Respectfully submitted,

*Sar:*  *6/10/03 45,409*  
Ivor R. Elrifi, Reg. No. 39,529  
Attorney for Applicants  
MINTZ, LEVIN, COHN, FERRIS,  
GLOVSKY and POPEO, P.C.  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241

Dated: September 30, 2003


TRA 1838061v1

Express Mail No. EV312712165US

Date of Deposit: September 30, 2003

Please type a plus sign (+) in this box

+



Modified Form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	09/666,876
Filing Date	September 20, 2000
First Named Inventor	Ellington et al.
Group Art Unit	1639
Examiner Name	Jon D. Epperson, Ph.D.
Attorney Docket Number	23239-301B

**U.S. PATENT DOCUMENTS**

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1	5,589,332	12/31/96	Shih, et al.			05/09/94
	A2	5,834,186	11/10/98	George, et al.			06/02/95
	A3	6,201,113	03/13/01	Todd, et al.			8/11/00

**FOREIGN PATENT DOCUMENTS**

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
	B4	WO 96/27026	Intelligene, LTD.	09/06/96		
	B5	WO 99/47704	Jenne, et al.	09/23/99		
	B6	WO 99/50277	University of Utah Research Foundation	10/07/99		

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C4	Breaker (1996). Curr Opin Biotech 7: 442-448.
	C5	Breaker (1997). Nat Biotech 15: 427-431.
	C6	Breaker (1997). Chem Rev 97: 371-390.
	C7	Breaker (1999). Horizon Scientific Press, Wymondham UK: 1-19.
	C8	Breaker (2002). Curr Opin Biotech 13: 31-39.
	C9	Breaker (1997). Curr Opin Chem Biol 1: 26-31.
	C10	Carmi, et al. (1996). Chem and Biol 3: 1039-1046.
	C11	Gold (2002). Nat Biotech 20: 671-672.
	C12	Hamaguchi, et al. (2001). Anal Biochem 294: 126-131.
	C13	Hartig, et al. (2002). Nat Biotech 20: 717-722.
	C14	Haseloff, et al. (1988). Nature 334: 585-591.
	C15	Jenne, et al. (2001). Nat Biotech 19: 56-61.
	C16	Koizumi, et al., (1999). Nat Struct Biol 6: 1062-1071.
	C17	Li and Breaker (1999). Curr Opin Struct Biol 9: 315-323.
	C18	Li and Breaker (1999). Proc Natl Acad Sci USA 96: 2746-2751.
	C19	Marshall, et al. (1999). Nat Struct Biol 6: 992-994.
	C20	Robertson and Ellington (1999). Nat Biotech 17: 62-66.
	C21	Robertson & Ellington (2000) 3 Nucleic Acids Res 28: 1751-1759.

RECEIVED

OCT 10 2003

TECH CENTER 1600/2900

RECEIVED  
Page 2 of 2  
OCT 10 2003

TECH CENTER 1600/2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C22	Robertson and Ellington (2001). Nat Biotech 19: 650-655.
	C23	Seetharaman, et al. (2001). Nat Biotech 19: 336-341.
	C24	Soukup and Breaker (1999). RNA 5: 1308-1325.
	C25	Soukup and Breaker (1999). Structure 7: 783-791.
	C26	Soukup and Breaker (1999). Tren Biotech 17: 469-476.
	C27	Soukup and Breaker (2000). Ribo Biochem Biotech Eaton Publ: 149-170.
	C28	Soukup and Breaker (1999). Proc Natl Acad Sci 96: 3584-3589.
	C29	Tang and Breaker (1997). Chem Biol 4: 453-459.
	C30	Tang and Breaker (1998). Nuc Acids Res 26: 4214-4221.
	C31	Tang and Breaker (1997). RNA 3: 914-925.
	C32	Tuschl, et al. (1994). Science 266: 785-789.
	C33	Weeks (1997). Curr Opin Struct Biol 7: 336-342.
	C34	International Search Report for PCT/US 02/25319, mailed July 17, 2003.

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.  
Include copy of this form with next communication to applicant.